GB202107182D0 - Nanoparticle delivery system for production of engineered extracellular vesicles - Google Patents

Nanoparticle delivery system for production of engineered extracellular vesicles

Info

Publication number
GB202107182D0
GB202107182D0 GBGB2107182.4A GB202107182A GB202107182D0 GB 202107182 D0 GB202107182 D0 GB 202107182D0 GB 202107182 A GB202107182 A GB 202107182A GB 202107182 D0 GB202107182 D0 GB 202107182D0
Authority
GB
United Kingdom
Prior art keywords
production
delivery system
extracellular vesicles
nanoparticle delivery
engineered extracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2107182.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evox Therapeutics Ltd
Original Assignee
Evox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evox Therapeutics Ltd filed Critical Evox Therapeutics Ltd
Priority to GBGB2107182.4A priority Critical patent/GB202107182D0/en
Publication of GB202107182D0 publication Critical patent/GB202107182D0/en
Priority to PCT/EP2022/063655 priority patent/WO2022243484A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2107182.4A 2021-05-19 2021-05-19 Nanoparticle delivery system for production of engineered extracellular vesicles Ceased GB202107182D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2107182.4A GB202107182D0 (en) 2021-05-19 2021-05-19 Nanoparticle delivery system for production of engineered extracellular vesicles
PCT/EP2022/063655 WO2022243484A1 (en) 2021-05-19 2022-05-19 Nanoparticle delivery system for production of engineered extracellular vesicles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2107182.4A GB202107182D0 (en) 2021-05-19 2021-05-19 Nanoparticle delivery system for production of engineered extracellular vesicles

Publications (1)

Publication Number Publication Date
GB202107182D0 true GB202107182D0 (en) 2021-06-30

Family

ID=76550772

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2107182.4A Ceased GB202107182D0 (en) 2021-05-19 2021-05-19 Nanoparticle delivery system for production of engineered extracellular vesicles

Country Status (2)

Country Link
GB (1) GB202107182D0 (en)
WO (1) WO2022243484A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
GB201609216D0 (en) * 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
EP3697447A4 (en) * 2017-10-16 2021-08-25 Aadigen, LLC Peptides and nanoparticles for intracellular delivery of mrna
GB201800921D0 (en) * 2018-01-19 2018-03-07 Evox Therapeutics Ltd Intracellular delivery of target silencing technology
GB201804291D0 (en) * 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
GB201809622D0 (en) * 2018-06-12 2018-07-25 Evox Therapeutics Ltd Engineering extracellular vesicles for affinity purification

Also Published As

Publication number Publication date
WO2022243484A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
EP3727351A4 (en) Engineered extracellular vesicles for enhanced tissue delivery
IL286556A (en) Extracellular vesicles for vaccine delivery
MX2018011202A (en) Therapeutic membrane vesicles.
BR112014029247A2 (en) lipid nanoparticle, pharmaceutical composition, method for making a lipid nanoparticle, product, method of treating a disorder, and delivery system
HK1247964A1 (en) Extracellular vesicles for agent delivery
HK1202418A1 (en) Drug delivery system for sustained delivery of bioactive agents
EP2707146A4 (en) Nozzles for nasal drug delivery
HK1201089A1 (en) Functionalized nanoparticles for intracellular delivery of biologically active molecules
EP2792367A4 (en) Lipid nanoparticles for drug delivery system containing cationic lipids
NZ743320A (en) Method for preparing polymeric micelle containing anionic drug
MX368844B (en) Imidazoline derivatives, preparation methods thereof, and their applications in medicine.
MX2014013858A (en) Method for treating a gd2 positive cancer.
SG11201503729QA (en) Yogurt and production method thereof, production method of lactic acid bacteria extracellular functional product and agent for enhancing yield of lactic acid bacteria extracellular functional product
MX2015001561A (en) Vesicles which include epidermal growth factor and compositions that contain same.
MX352176B (en) Process for producing inorganic particulate material.
EP2879510C0 (en) Production of soluble protein products from hemp ("h701")
EP2744449A4 (en) Drug delivery system and method of manufacturing thereof
EP3950060A4 (en) Composition for promoting secretion of extracellular vesicles
UA111434C2 (en) Pharmaceutical composition containing fimasartan and hydrochlorothiazide
GB202107182D0 (en) Nanoparticle delivery system for production of engineered extracellular vesicles
EP2833869A4 (en) Method of preparing composition for delivering an anionic drug
IT1399862B1 (en) VERTICAL AXIS MACHINE FOR THE PRODUCTION OF FILTER BAGS WITH INFUSION PRODUCTS
TN2014000532A1 (en) N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
MX2016006738A (en) Process for producing inorganic particulate material.
EP2747802A4 (en) Drug delivery system and method of manufacturing thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)